Document is current

Article History

Accepted: 4 November 2024

First Online: 29 November 2024

Declarations

:

: The study was funded by Apellis Pharmaceuticals, Inc., and Swedish Orphan Biovitrum AB.

: Ryan L. Crass was an employee at Apellis Pharmaceuticals at the time of the study. Grant Langdon is a consultant to Swedish Orphan Biovitrum and does not own stock and/or stock options. Brandon Smith, Sven Adriaens, and Sunny Chapel have no conflicts that are directly relevant to the content of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: The datasets generated and/or analyzed during the current study are not publicly available. Data used for this study are from Apellis Pharmaceuticals, Inc., and were used under license for the current study. Therefore, restrictions apply to the availability of these data, which cannot be made publicly available. Access to this dataset may be granted to other interested parties by Apellis Pharmaceuticals, Inc., but may be subject to limitations based on how the original clinical trial data were acquired.

: Not applicable.

: All authors were involved in the design of the model, preparation of the manuscript, and review and approval of the manuscript.